A challenging drug development process in the era of personalized medicine

Drug Discov Today. 2011 Oct;16(19-20):891-7. doi: 10.1016/j.drudis.2011.09.010. Epub 2011 Sep 18.


After years of hesitation a larger number of pharmaceutical and biotech companies are now supporting the idea of a more individualized pharmacotherapy. The companies that are now involved in this research-demanding area will have to face several challenges. The key factor for success will be an in-depth molecular understanding of the pathophysiology and the mechanism of the drug under development. The one-disease-one-drug-one-target paradigm that has been prevailing for decades is history. Most diseases are heterogeneous and based on molecular profiling they can be divided into biological subgroups that each requires a specific pharmacological intervention.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Disease / etiology
  • Disease / genetics
  • Drug Discovery / methods*
  • Humans
  • Models, Biological*
  • Molecular Diagnostic Techniques
  • Pharmaceutical Preparations / administration & dosage
  • Pharmaceutical Preparations / metabolism
  • Precision Medicine / methods*
  • Systems Biology


  • Biomarkers
  • Pharmaceutical Preparations